West Pharmaceutical Services (United States)
WST
$357.66
+1.13%
West Pharmaceutical Services is a key supplier of elastomer-based packaging components, containment solutions, and auto-injectors to the pharmaceutical, biotechnology, and generic drug industries. As a market leader in injectable drug packaging, the company benefits from its proprietary product portfolio, which accounts for about 80% of revenue, and its global reach with 55% of sales from international markets. The current investor narrative centers on accelerating growth driven by surging demand for GLP-1 receptor agonists, as highlighted by the company's recent earnings beat and raised guidance in April 2026. This positions West as a critical enabler in the high-growth injectable drug market, attracting attention for its potential to sustain above-trend expansion.…
WST
West Pharmaceutical Services (United States)
$357.66
Related headlines
WST 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $464.96 and implied upside of +30.0% versus the current price.
Average Target
$464.96
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$286 - $465
Analyst target range
West Pharmaceutical is covered by 7 analysts, with a consensus leaning bullish. The average analyst target price is not explicitly provided, but based on the estimated EPS average of $12.44 and a forward P/E of 38.3x, the implied target is approximately $476. This would represent about 30% upside from the current price of $365.74. The consensus recommendation is likely a Buy, given the recent upgrades and positive ratings from firms like Evercore ISI (Outperform), KeyBanc (Overweight), and UBS (Buy). Barclays maintains an Equal Weight rating, indicating some caution. The estimated EPS range is $12.13 to $12.77, and revenue estimates range from $4.03 billion to $4.19 billion, suggesting confidence in continued growth. The high target of $12.77 EPS implies strong execution on GLP-1 demand and margin expansion, while the low target of $12.13 EPS factors in potential headwinds such as currency or slower adoption. The spread in estimates is relatively narrow, indicating high conviction among analysts. Recent ratings have been stable, with no downgrades, and the April 2026 guidance raise reinforces positive sentiment. The wide target spread (if available) would signal uncertainty, but the data suggests a tight range, reflecting confidence in the company's trajectory.
Drowning in data?
Find the real signal!
WST Technical Analysis
West Pharmaceutical is in a strong uptrend, with the stock up 65.3% over the past year, significantly outperforming the S&P 500's 19.1% gain. The current price of $365.74 sits at 99.5% of its 52-week range ($206.80–$367.66), indicating the stock is near its all-time high and reflecting robust momentum. This positioning near the top of the range suggests bullish sentiment but also raises caution about potential overextension, as the stock has rallied sharply from its low. Short-term momentum is accelerating, with a 1-month gain of 17.2% and a 3-month gain of 43.5%, far outpacing the S&P 500's respective returns of -1.3% and 13.6%. The relative strength over 1-month (18.4%) and 3-month (30.0%) confirms strong near-term buying pressure, with no signs of divergence from the longer-term uptrend. The stock's beta of 1.16 indicates slightly higher volatility than the market, but the recent price action suggests a powerful trend that could continue. Key support lies near the 52-week low of $206.80, while resistance is at the 52-week high of $367.66. A breakout above $367.66 would signal a continuation of the uptrend, potentially opening the door to further gains. Conversely, a pullback below recent support levels (e.g., $330) could indicate a short-term correction, but the overall trend remains bullish. The stock's beta of 1.16 implies moderate volatility, meaning it may experience larger swings than the market, which is important for risk management.
Beta
1.16
1.16x market volatility
Max Drawdown
-24.8%
Largest decline past year
52-Week Range
$207-$368
Price range past year
Annual Return
+58.1%
Cumulative gain past year
| Period | WST Return | S&P 500 |
|---|---|---|
| 1m | +6.9% | +2.0% |
| 3m | +39.4% | +10.6% |
| 6m | +29.8% | +8.3% |
| 1y | +58.1% | +20.4% |
| ytd | +29.4% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
WST Fundamental Analysis
Revenue growth is accelerating, with the most recent quarter (Q4 2025) reporting $805 million, up 7.6% year-over-year from $748.5 million in Q4 2024. This marks an acceleration from the prior quarter's 7.7% growth (Q3 2025: $804.3M vs. $746.9M) and a significant improvement from Q1 2025's 0.4% growth. The Proprietary Products segment, which generated $661.8 million in Q4 2025 (82% of total revenue), is the primary growth driver, fueled by demand for components used in GLP-1 drugs and biologics. The Contract Manufactured Products segment contributed $143.2 million, providing additional diversification. The company's profitability is solid, with net income of $132.1 million in Q4 2025, up from $130.1 million a year ago, and a net margin of 16.4%. Gross margin improved to 37.8% in Q4 2025 from 36.7% in Q4 2024, reflecting better product mix and operating leverage. Operating margin was 19.5%, while EBITDA margin reached 26.0%, indicating efficient cost management. The company has been consistently profitable, with EPS of $1.83 in Q4 2025 versus $1.79 in Q4 2024. West's balance sheet is strong, with a debt-to-equity ratio of just 0.13 and a current ratio of 3.02, indicating ample liquidity. Free cash flow for the trailing twelve months was $468.9 million, providing a free cash flow yield of approximately 2.4% based on the current market cap. The company generated $251.1 million in operating cash flow in Q4 2025, easily covering capital expenditures of $76.1 million. Return on equity (ROE) stands at 15.5%, reflecting efficient capital use. The low debt levels and strong cash generation suggest the company can fund growth internally without relying on external financing.
Quarterly Revenue
$805000000.0B
2025-12
Revenue YoY Growth
+7.55%
YoY Comparison
Gross Margin
37.75%
Latest Quarter
Free Cash Flow
$468900000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is WST Overvalued?
Given that net income is positive ($132.1 million in Q4 2025), the primary valuation metric is the P/E ratio. The trailing P/E is 40.3x, while the forward P/E is 38.3x, implying the market expects earnings growth to continue. The gap between trailing and forward P/E suggests modest growth expectations, but the absolute level indicates a premium valuation. Compared to the industry average P/E (not provided, but typically in the low 20s for medical instruments), West's P/E of 40.3x represents a significant premium, likely justified by its superior growth profile and market position. The PEG ratio of 34.0x suggests the stock is expensive relative to its near-term earnings growth, but this may understate long-term potential given the GLP-1 tailwind. Historically, West's P/E has ranged from about 30x to 63x over the past five years. The current trailing P/E of 40.3x is near the middle of this range, suggesting it is not at extreme levels. However, the price-to-sales ratio of 6.5x is elevated compared to historical averages, reflecting the market's willingness to pay a premium for revenue growth. The EV/EBITDA of 27.0x also indicates a premium valuation. Overall, the stock trades at a premium to both its own history and the sector, but this is supported by accelerating growth and strong profitability.
PE
40.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 30x~63x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.0x
Enterprise Value Multiple
